Skip to content
ClinCalc Pro
Menu
Calculators Drugs Pathways AI Dx Donate Get the App
Direct Oral Anticoagulant — VTE Prophylaxis Post-Surgery

Rivaroxaban (Perioperative VTE Prophylaxis)

Brand names: Xarelto

Rivaroxaban is an oral direct factor Xa inhibitor used for venous thromboembolism prophylaxis after major orthopaedic surgery such as hip and knee replacement.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

Rivaroxaban directly and selectively inhibits activated factor Xa, reducing thrombin generation and clot formation.

Prescribing in practice

  • Bleeding is the principal risk — observe a safe interval after surgery and after neuraxial anaesthesia or catheter removal before starting or resuming, to minimise the danger of spinal or epidural haematoma.
  • Avoid in significant renal impairment and with strong dual CYP3A4 and P-glycoprotein inhibitors or inducers, which substantially alter exposure.
  • There is no immediate routine laboratory monitoring; manage major bleeding with the specific reversal agent or prothrombin complex concentrate as locally directed.

Monitoring

Monitor for bleeding, renal function and haemoglobin rather than routine coagulation assays, and confirm appropriate timing around regional anaesthesia.

Counselling the patient

  • This tablet thins the blood to prevent clots in the legs and lungs after your joint surgery.
  • Report unusual bruising, bleeding that will not stop, or black stools.
  • Take it as instructed and do not miss doses.

Evidence & guidelines

Rivaroxaban is a licensed and guideline-supported option for VTE prophylaxis following elective hip and knee replacement.

Reference: NICE TA170/TA261; Xarelto SPC; ESRA Neuraxial Anaesthesia and Anticoagulants Guidelines 2021; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.

Calculators
Pathways